Back to Search Results

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.

Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain. Electronic address: pedroe.mondejar@carm.es. Cystic Fibrosis Unit, Medical-Surgical Unit for Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Sevilla, Spain; Centre for Biomedical Research Network of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Cystic Fibrosis and Bronchiectasis Unit, Instituto de Investigacion, Hospital Universitario de la Princesa, Madrid, Spain. Pediatric Pulmonology and Allergy Unit, Cystic Fibrosis Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain. Adult Cystic Fibrosis Unit, Pulmonology Service, Hospital Universitario 12 de Octubre, Madrid, Spain. Pulmonology Service, Cystic Fibrosis and Bronchiectasis Unit, Hospital Universitario La Paz, Madrid, Spain. Adult Cystic Fibrosis Unit, Pulmonology Service, Hospital Vall D'Hebron, Barcelona, Spain; Vall D'Hebron Institut de Recerca, Barcelona, Spain. Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain. Pulmonology Service. Hospital Clinico Universitario Virgen de La Arrixaca, Murcia, Spain. Osakidetza. Organización Sanitaria Integrada Ezkerraldea-Enkarterri-Cruces, Hospital Universitario Cruces, Paediatrics, Cystic Fibrosis Unit, Bizkaia, Spain. Cystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Biomedical Research Institute of Malaga (IBIMA), Universidad de Malaga, Spain. Cystic Fibrosis Unit, Pediatrics Service, Hospital Universitario Ramón y Cajal, Madrid, Spain. Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clínico Universitario, Valencia, Spain. Endocrinology and Nutrition Service, Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain. Cystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Pediatric Pulmonology and Cystic Fibrosis Unit, UGC de Pediatría, Hospital Regional Universitario, Málaga, Spain. Lung Transplantation and Cystic Fibrosis Unit, Hospital Universitario La Fe, Universidad de Valencia, Valencia, Spain. Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain; Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. Cystic Fibrosis Unit, Pediatric Pulmonology and Allergy Unit, Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain; Faculty of Medicine, Universidad Autonoma de Barcelona, Spain.

Respiratory medicine. 2020;:106062
Full text from:

Other resources

Abstract

BACKGROUND Given the high incidence of confirmed infection by SARS-CoV-2 and mortality by COVID-19 in the Spanish population, its impact was analysed among persons with Cystic Fibrosis (CF) as a group at risk of a worse evolution. The possible causes of the incidence observed in them are explained and how CF Units have faced this health challenge is detailed. METHODS Retrospective descriptive observational study, for which a Spanish CF Patients with Confirmed COVID-19 Registry is created, requesting information on number of people affected between 8 March-16 May 2020 and their clinical-demographic characteristics from the CF Units participating in the European Cystic Fibrosis Society Patient Registry (ECFSPR). The accumulated incidence is calculated, compared with that of the general population. Additionally, a survey (CF-COVID19-Spain) is carried out on prevention of SARS-CoV-2 infection, workings of CF Units and possible reasons for the incidence observed. RESULTS COVID-19 was diagnosed in eight CF patients, one of whom had received a lung transplant. The accumulated incidence was 32/10000 in CF patients and 49/10000 in the general population. General death rate was 5.85/10000 while no CF patients included in the ECFSPR died. The characteristics of those affected and the results of the survey are described. CONCLUSIONS Despite being considered a disease at high risk of severe COVID-19, the low incidence and mortality in CF patients in Spain contrasts with the figures for the general population. The possible factors that would explain such findings are discussed, with the help of the results of the CF-COVID19-Spain survey.

Methodological quality

Publication Type : Observational Study

Metadata